{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Neoplasm+Epithelial&page=19", "query": { "condition": "Ovarian Neoplasm Epithelial", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 1065, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Neoplasm+Epithelial&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Neoplasm+Epithelial&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T01:37:44.302Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00316407", "title": "Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Epithelial Cancer Stage III", "Stage IV Ovarian Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "lapatinib (GW572016)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Swedish Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2005-08", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2011-02-18", "last_synced_at": "2026-10-23T01:37:44.302Z", "location_count": 2, "location_summary": "Albuquerque, New Mexico • Seattle, Washington", "locations": [ { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00316407" }, { "nct_id": "NCT05445778", "title": "Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Mirvetuximab soravtansine plus Bevacizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 520, "start_date": "2023-03-15", "completion_date": "2032-05", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-23T01:37:44.302Z", "location_count": 74, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Irvine, California + 62 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05445778" }, { "nct_id": "NCT07278336", "title": "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "ABBV-901", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2025-11-27", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-23T01:37:44.302Z", "location_count": 8, "location_summary": "Duarte, California • Irvine, California • Denver, Colorado + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07278336" }, { "nct_id": "NCT07182149", "title": "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HNSCC", "ESCC", "Esophageal Adenocarcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Ovarian Cancer", "NSCLC", "Cervical Cancer", "Endometrial Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "NRM-823", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Normunity AccelCo, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-10-30", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-23T01:37:44.302Z", "location_count": 18, "location_summary": "Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07182149" }, { "nct_id": "NCT06463028", "title": "Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Serabelisib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Faeth Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2024-12-12", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-23T01:37:44.302Z", "location_count": 18, "location_summary": "La Jolla, California • San Francisco, California • Miami Beach, Florida + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06463028" }, { "nct_id": "NCT01747798", "title": "Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Recurrent Fallopian Tube Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "auranofin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2012-11-02", "completion_date": "2015-04-06", "has_results": false, "last_update_posted_date": "2019-08-02", "last_synced_at": "2026-10-23T01:37:44.302Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01747798" }, { "nct_id": "NCT01296035", "title": "Panitumumab and Gemcitabine in Relapsed Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Panitumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Women and Infants Hospital of Rhode Island", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 8, "start_date": "2011-02", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2015-08-25", "last_synced_at": "2026-10-23T01:37:44.302Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01296035" }, { "nct_id": "NCT04606914", "title": "Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "mirvetuximab soravtansine (MIRV; IMGN853)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 70, "start_date": "2021-05-27", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-23T01:37:44.302Z", "location_count": 9, "location_summary": "Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Oxford", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT04606914" }, { "nct_id": "NCT06674811", "title": "Biomarkers of Resiliency In Childhood Cancer Surgery", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pediatric Cancer", "Neuroblastoma", "Sarcoma", "Wilms Tumor and Other Childhood Kidney Tumors", "Childhood Soft Tissue Sarcoma", "Childhood Bone Sarcoma", "Childhood Malignant Intestinal Neoplasm", "Childhood Malignant Liver Neoplasm", "Childhood Malignant Lung Neoplasm", "Childhood Malignant Ovarian Neoplasm", "Childhood Malignant Pleural Neoplasm", "Childhood Neuroblastic Tumor", "Childhood Sarcoma" ], "interventions": [ { "name": "Wearing Smartwatch", "type": "OTHER" }, { "name": "Patient Report Outcomes", "type": "OTHER" }, { "name": "Blood Draw", "type": "OTHER" }, { "name": "Clinical Data Review", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "3 Years to 25 Years" }, "enrollment_count": 40, "start_date": "2025-01-15", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-23T01:37:44.302Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06674811" }, { "nct_id": "NCT00407563", "title": "Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accelerated Community Oncology Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2007-01", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2012-04-05", "last_synced_at": "2026-10-23T01:37:44.302Z", "location_count": 11, "location_summary": "Little Rock, Arkansas • La Verne, California • Athens, Georgia + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Verne", "state": "California" }, { "city": "Athens", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Coeur d'Alene", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT00407563" } ] }